APA

Jensen J., Lundgren B., Hein L., Mohr T., Petersen P. L., Andersen L. H., Lauritsen A. O., Hougaard S., Mantoni T., Bømler B., Thornberg K. J., Thormar K., Løken J., Steensen M., Carl P., Petersen J. A., Tousi H., Søe-Jensen P., Bestle M., Hestad S., Andersen M. H., Fjeldborg P., Larsen K. M., Rossau C., Thomsen C. B., Ostergaard C., Kjaer J., Grarup J. & Lundgren J. D. (20081118). The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. : BMC infectious diseases.

Chicago

Jensen Jens-Ulrik, Lundgren Bettina, Hein Lars, Mohr Thomas, Petersen Pernille L, Andersen Lasse H, Lauritsen Anne O, Hougaard Sine, Mantoni Teit, Bømler Bonnie, Thornberg Klaus J, Thormar Katrin, Løken Jesper, Steensen Morten, Carl Peder, Petersen J Asger, Tousi Hamid, Søe-Jensen Peter, Bestle Morten, Hestad Søren, Andersen Mads H, Fjeldborg Paul, Larsen Kim M, Rossau Charlotte, Thomsen Carsten B, Ostergaard Christian, Kjaer Jesper, Grarup Jesper and Lundgren Jens D. 20081118. The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. : BMC infectious diseases.

Harvard

Jensen J., Lundgren B., Hein L., Mohr T., Petersen P. L., Andersen L. H., Lauritsen A. O., Hougaard S., Mantoni T., Bømler B., Thornberg K. J., Thormar K., Løken J., Steensen M., Carl P., Petersen J. A., Tousi H., Søe-Jensen P., Bestle M., Hestad S., Andersen M. H., Fjeldborg P., Larsen K. M., Rossau C., Thomsen C. B., Ostergaard C., Kjaer J., Grarup J. and Lundgren J. D. (20081118). The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. : BMC infectious diseases.

MLA

Jensen Jens-Ulrik, Lundgren Bettina, Hein Lars, Mohr Thomas, Petersen Pernille L, Andersen Lasse H, Lauritsen Anne O, Hougaard Sine, Mantoni Teit, Bømler Bonnie, Thornberg Klaus J, Thormar Katrin, Løken Jesper, Steensen Morten, Carl Peder, Petersen J Asger, Tousi Hamid, Søe-Jensen Peter, Bestle Morten, Hestad Søren, Andersen Mads H, Fjeldborg Paul, Larsen Kim M, Rossau Charlotte, Thomsen Carsten B, Ostergaard Christian, Kjaer Jesper, Grarup Jesper and Lundgren Jens D. The Procalcitonin And Survival Study (PASS) - a randomised multi-center investigator-initiated trial to investigate whether daily measurements biomarker Procalcitonin and pro-active diagnostic and therapeutic responses to abnormal Procalcitonin levels, can improve survival in intensive care unit patients. Calculated sample size (target population): 1000 patients. : BMC infectious diseases. 20081118.